Want to see PRPH full AI Analyst Report?
Prophase Labs (PRPH) AI Stock Analysis
Prophase Labs
(Other OTC:PRPH)
PRPH scores low primarily due to sharply deteriorated financial performance (collapsed revenue, extreme losses, accelerating cash burn, and negative equity). Technicals also remain weak with the stock below all major moving averages and negative MACD. Valuation is not meaningfully supportive because earnings are negative and no dividend is indicated.
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $140.16K
- Dividend Yield
- ―
- Average Volume (3M)
- 319.27K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.99
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Prophase Labs Business Overview & Revenue Model
Company Description
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products...
How the Company Makes Money
ProPhase Labs generates revenue primarily through (1) selling consumer products and (2) providing diagnostic laboratory services. In its consumer segment, revenue is earned by manufacturing and/or sourcing branded products and selling them through re...
Prophase Labs Earnings Call Summary
The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the ProPhase Labs, Inc.'s third-quarter 2025 earnings call, Chairman and CEO Ted Karkus provided several metrics and strategic insights. He emphasized the importance of shareholder voting on a critical proxy, which could impact strategic initiatives. The company is targeting collections of around $150 million in uncollected COVID testing claims, with expectations to net at least $50 million after discounts and fees. Karkus also discussed the potential of the BSmart esophageal cancer test, estimating a target market of $7-14 billion, and highlighted Nebula Genomics' restructuring towards profitability. ProPhase Labs' current market cap stands at approximately $12 million, with 46.1 million shares outstanding. Karkus addressed the possibility of a reverse stock split to maintain Nasdaq compliance, aiming to capitalize on the company's undervalued stock and significant asset potential.
Prophase Labs Financial Statement Overview
Summary
Financials are very weak: revenue collapsed (from $122.6M in 2022 to ~$3.2M TTM), margins and profitability are deeply negative (TTM operating margin ~-397%, net margin ~-717%), and cash burn is severe (TTM operating/free cash flow about -$30.7M). The balance sheet has also deteriorated with stockholders’ equity turning negative (~-$3.1M TTM), limiting flexibility despite moderate debt (~$9.7M).
Income Statement
14Very NegativeBalance Sheet
22NegativeCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.16M | 4.34M | 6.77M | 44.38M | 122.65M | 79.04M |
| Gross Profit | 517.00K | 1.38M | -150.00K | 16.24M | 70.65M | 32.81M |
| EBITDA | -7.15M | -11.39M | -32.34M | -14.83M | 28.73M | 10.02M |
| Net Income | -22.64M | -14.74M | -53.36M | -16.78M | 18.46M | 6.27M |
Balance Sheet | ||||||
| Total Assets | 57.41M | 59.87M | 63.20M | 91.93M | 87.65M | 89.30M |
| Cash, Cash Equivalents and Short-Term Investments | 20.00K | 90.00K | 678.00K | 4.74M | 17.44M | 17.51M |
| Total Debt | 9.12M | 8.62M | 24.57M | 18.46M | 6.96M | 14.90M |
| Total Liabilities | 60.52M | 56.36M | 55.85M | 42.54M | 24.02M | 30.67M |
| Stockholders Equity | -3.11M | 3.51M | 7.35M | 49.38M | 63.63M | 58.63M |
Cash Flow | ||||||
| Free Cash Flow | -30.69M | -8.34M | -18.44M | -14.50M | 24.63M | -17.85M |
| Operating Cash Flow | -30.69M | -8.34M | -17.54M | -11.35M | 28.55M | -13.62M |
| Investing Cash Flow | 11.08K | 920.00K | 2.42M | -1.37M | -2.08M | -19.67M |
| Financing Cash Flow | 11.30M | 6.84M | 14.19M | 5.76M | -26.02M | 35.13M |
Prophase Labs Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPH, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 37.38 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRPH.
Prophase Labs Risk Analysis
Prophase Labs disclosed 63 risk factors in its most recent earnings report. Prophase Labs reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskProphase Labs Peers Comparison
Overall Rating
AYTU62Neutral
TXMD58Neutral
YCBD43Neutral- PRPH41Neutral
IMCC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AYTU | 62Neutral | $20.98M | -1.42 | -52.89% | ― | -13.27% | 27.11% |
| TXMD | 58Neutral | $20.83M | -96.28 | -0.80% | ― | 27.78% | 52.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| YCBD | 43Neutral | $4.29M | -1.29 | -34.25% | ― | 10.01% | 95.01% |
| PRPH | 41Neutral | $139.52K | -0.00 | -1358.66% | ― | ― | ― |
| IMCC | 37Underperform | $1.30M | -0.03 | 841.81% | ― | -11.91% | -285.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRPH | Prophase Labs | 0.01 | -2.91 | -99.66% | |
| TXMD | Therapeuticsmd Inc | 1.81 | 0.64 | 54.70% | |
| AYTU | Aytu BioScience | 1.94 | -0.19 | -8.92% | |
| YCBD | Cbdmd INc | 0.40 | -0.41 | -51.11% | |
| IMCC | Im Cannabis Corp | 0.75 | -37.65 | -98.05% |
Prophase Labs Corporate Events
ProPhase Labs Secures Convertible Loan to Strengthen Liquidity
NeutralOn July 31, 2026, ProPhase Labs, Inc. entered into a senior secured convertible loan agreement with J.J. Astor & Co. for an original principal amount of $2,085,000 in exchange for funding of $1,500,000, before fees and reserves. The company recei...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026